- PIK3CA mutations
	- ~40% of advanced HR+, HER2-
## local

### studies
- ER+
	- high-risk
		- SOFT, TEXT: [[aromatase inhibitor]] or [[tamoxifen]] x5y w [[ovarian suppression]]
## metastatic

### studies
- HER2+, ER+
	- CLEOPATRA: [[pertuzumab]] + [[trastuzumab]] + [[docetaxel]] is good. 1L SOC if chemo candidate.
	- PERTAIN [[2018]]: [[pertuzumab]] + [[trastuzumab]] + [[aromatase inhibitor]]. [[Ongoing ]][[open-label]], [[phase II ]][[RCT]], adding pertuzumab to trastuzumab+AI. A little more than half also got chemo. N= ~250.
		- stratified median PFS: 18.89mo w triplet, 15.80mo w doublet
		- ORR difference not statistically significant
		- DoR 27.1mo w triplet, 15.1mo w doublet.
- HER2-, HR+
	- I3Y-MC-JPBO: [[abemaciclib]] in BC, [[NSCLC]], [[melanoma]].
		- BC: N=7, 4 w brain mets. OS 8.4mo (historical OS <=4mo). OR: SD in 5/7, PD in 2/7. Brain OR: CR in 1/4, SD in 1/4, PD in 2/4.
	- [SOLAR 1](https://www.nejm.org/doi/10.1056/NEJMoa1813904): apelisib + fulvestrant works well, but is tough to tolerate.
		- PFS 11.0mo vs 5.7mo.
		- FDA approval: POD on or after endocrine-based regimen (HR+, HER2-, PIK3CAmut, adv/met)
		- 36.6% grade 3-4 hyperglycemia, 9.9% grade 3-4 rash, 6.7% grade 3 diarrhea (no grade 4). Discontinuation rate 25%.